Back to search

Article

The costs and benefits of an early access scheme for oncology medicines in Ireland

2025-10-31

Abstract excerpt

<h4>Background</h4> Access to new oncology medicines is subject to delays in many countries due to lengthy appraisal processes. This study examines the cost to the Irish healthcare system of implementing a cost- sharing agreement to expedite access to oncology medicines. <h4>Methods</h4> The hypothetical cost of implementing an early access scheme in Ireland was estimated for oncology medicines commencing apprai...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
5561eac5-564e-5191-96d8-64d7dc576908
DOI
10.1101/2025.10.30.25339127
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The costs and benefits of an early access scheme for oncology medicines in IrelandDOI 10.1101/2025.10.30.25339127
Quantifying the Dual Value and Governance Risks of Early Access Programs in Oncology: A Single-Centre Analysis and National Policy FrameworkSemantic proximity
Time to Patients’ Access to New Medicines in Greece: Evaluation of Health Technology Assessment (HTA) Process from July 2018 until January 2021.Semantic proximity
Access to Essential and Innovative Anti-cancer Medicines: A Longitudinal Study in Nanjing, ChinaSemantic proximity
Methodological Challenges in Dutch HTA of Non-Oncological Orphan Drugs: A Retrospective Analysis and Price Comparison Using different Pricing ModelsSemantic proximity
Free of charge medicine schemes in the NHS. A local and regional Drug and Therapeutic Committees (DTC) experience.Semantic proximity
How the HTAR will contribute to a value-based decision making for medicinal products across the EUSemantic proximity
Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countriesSemantic proximity
Does The Reformed Cancer Drug Fund Generate Evidence On Effectiveness? A Cross-sectional Analysis On Publicly Accessible DocumentationSemantic proximity
Adaptive health technology assessments to inform oncology based priority setting in IndiaSemantic proximity
Launch Sequencing of Pharmaceuticals with Multiple Therapeutic Indications: Evidence from Seven CountriesSemantic proximity
Assessment of anticancer drug utilization pattern and patients’ survival—A single center experience from Saudi ArabiaSemantic proximity
The impact of the national centralized drug procurement on the use of original and generic targeted anti- tumor drugs in Hohhot, China: an interrupted time-series analysisSemantic proximity
Select a neighboring publication to make it the new centre.